Sign in Subscribe
Social services

Senator Warren Urges O'Neill to Recuse Himself from Biotech Companies He Has Worked With

Strategic Insights

— 2 min read

As the nomination of James O'Neill for Deputy Secretary of the Department of Health and Human Services (HHS) approaches the Senate Finance Committee's vote on Thursday, May 15, 2025, Senator Elizabeth Warren (D-Mass.) has written to Mr. O'Neill, expressing concerns about his relationships with biomedical companies regulated by HHS. Senator Warren's letter highlights Mr. O'Neill's ties to the pharmaceutical industry, including his involvement with ADvantage Therapeutics, a company developing an Alzheimer's drug that requires FDA approval. Mr. O'Neill has agreed to recuse himself from matters related to ADvantage for one year, but Senator Warren has urged him to commit to a four-year recusal to mitigate any appearance of a conflict of interest.

Senator Warren's concerns about Mr. O'Neill's relationships with biotech companies are further exacerbated by his potential influence over the FDA's approvals process as Deputy HHS Secretary. As a result, the senator has asked Mr. O'Neill to commit to recusing himself from matters involving companies he has worked with for four years after leaving his position. This would be similar to the agreements made by former FDA Commissioner Robert Califf and former NIH Director Monica Bertagnolli, who committed to recusing themselves from their former clients' matters for four years.

Key Takeaways:

  • Senator Elizabeth Warren has written to James O'Neill, the nominee for Deputy Secretary of HHS, expressing concerns about his relationships with biomedical companies regulated by HHS.
  • Mr. O'Neill has ties to the pharmaceutical industry, including his involvement with ADvantage Therapeutics, a company developing an Alzheimer's drug that requires FDA approval.
  • Mr. O'Neill has agreed to recuse himself from matters related to ADvantage for one year, but Senator Warren has urged him to commit to a four-year recusal to mitigate any appearance of a conflict of interest.
  • As Deputy HHS Secretary, Mr. O'Neill would have influence over the FDA's approvals process and could potentially sway HHS's decision-making to favor companies with which he has worked.
  • Senator Warren has asked Mr. O'Neill to commit to recusing himself from matters involving companies he has worked with for four years after leaving his position, similar to agreements made by former FDA Commissioner Robert Califf and former NIH Director Monica Bertagnolli.
  • Mr. O'Neill's ties to the pharmaceutical industry and his potential influence over the FDA's approvals process raise concerns about his post-government employment prospects.
  • Senator Warren has asked Mr. O'Neill to commit not to work for any company he regulates or otherwise interacts with during his time at HHS for four years after leaving government service.

Statistics:

  • 1 year: The length of time Mr. O'Neill has agreed to recuse himself from matters related to ADvantage.
  • 4 years: The length of time Senator Warren has urged Mr. O'Neill to commit to recusing himself from matters involving companies he has worked with.
  • 175 questions: The number of questions Senator Warren asked Mr. Robert F. Kennedy Jr. to answer ahead of his confirmation hearing for Secretary of Health and Human Services in January 2025.
  • 34 pages: The length of Senator Warren's letter to Mr. Robert F. Kennedy Jr. detailing her concerns with his nomination in January 2025.
  • 2 years: The length of time Mr. Robert Califf and Monica Bertagnolli, former FDA Commissioner and NIH Director, respectively, agreed to recuse themselves from their former clients' matters.

Sources:

  • "Text of Letter (PDF)"
  • United States Senator for Massachusetts -- Elizabeth Warren
  • Statement released by Senator Elizabeth Warren in response to the news that President-elect Donald Trump selected Robert F. Kennedy Jr. to serve as Secretary of Health and Human Services in November 2024
  • Remarks given by Senator Elizabeth Warren regarding the nomination of Mr. Robert F. Kennedy Jr. for Secretary of Health and Human Services in February 2025
  • Letter written by Senators Elizabeth Warren, Ron Wyden, Dick Durbin, Jeff Merkley, and Representative Lloyd Doggett to Dr. Mehmet Oz in December 2024
  • Statement released by Senator Elizabeth Warren in response to the announcement of the Presidential Transition Enhancement Act in March 2020

Read more